-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Kestra Medical Techs, Lowers Price Target to $17

Benzinga·04/09/2026 17:46:53
Listen to the news
Goldman Sachs analyst David Roman maintains Kestra Medical Techs (NASDAQ:KMTS) with a Neutral and lowers the price target from $22 to $17.